Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative…

Overview of attention for article published in Blood, November 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 26 news outlets

blogs: 2 blogs

Readers on

mendeley: 16 Mendeley

So far, Altmetric has seen 2 posts from 2 blogs.

CHMP empfiehlt die Zulassung von Ebvallo™ (Tabelecleucel) von Atara Biotherapeutics zur Behandlung der Epstein-Barr-Virus-positiven lymphoproliferativen Posttransplantationserkrankung

Oltnews, 15 Oct 2022

Evvallo™ auf dem Weg zur ersten zugelassenen allogenen T-Zell-Therapie Positive Stellungnahme aufgrund der Phase-III-Studie…

CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Neuro Central, 14 Oct 2022

EbvalloTM on Track to be the First Ever Allogeneic T-Cell Therapy…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.